Taysha Gene Therapies' investigational treatment for Rett syndrome has received breakthrough-therapy designation from the Food and Drug Administration. The clinical-stage biotechnology company on ...

For the first time, a treatment has altered the course of this inherited neurodegenerative disorder, offering a glimpse of a future where such diseases might be managed, not just endured.Though ...

Investing.com -- Taysha Gene Therapies Inc (NASDAQ:TSHA) stock soared 39% in premarket trading Thursday after the company announced that its gene therapy for Rett syndrome received Breakthrough ...

One oral presentation and five poster presentations will highlight exciting progress in AskBio’s pipeline and advancements in the company’s manufacturing technologies AskBio Inc. (AskBio), a gene ...

Breakthrough Therapy designation granted based on FDA’s review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized FDA ...

French biotech EG 427 has had success with its urinary incontinence DNA therapy, EG110A, showing a more than 80% reduction in episodes. In the Phase Ib/IIa trial (NCT06596291), the lowest dose of ...

He noted that cell and gene therapy—once a hot, up-and-coming area—is not a great space for biopharma professionals who aren’t on the manufacturing side, which is when therapies are getting close to ...

Treatment introduces an expansion of the scope of gene therapies that might lead to similar treatments for neurodegenerative diseases in other parts of the body ...

A beta blocker called propranolol has become popular for tempering anxiety and is generally safe, but it isn’t without risks.

How cell and gene therapy developers can lessen the chances of receiving FDA complete response letters through the use of proactive chemistry, manufacturing, and controls strategies.

In a preclinical study, UC Davis Comprehensive Cancer Center scientists have developed a highly targeted gene therapy that could revolutionize treatment for cancers linked to a common herpesvirus, ...

Now what this therapy is, is that it's basically a gene knockout therapy, and you give this to the patient via IV route for four hours. And what the company has shown us is that after one session of ...